

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-IX 3536	SERIAL NO. 09/339,922
	APPLICANT: Huse and Wu	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: June 24, 1999	GROUP: 1644

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
RC	US 6,180,370 B1	1/30/01	Queen et al.	435	69.6	6/7/95

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

MC	Biotechnology Newswatch 1/16/95 p. 11-12
MC	Biotechnology Newswatch 2/6/95 p. 11
M	Studnicka et al., "Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues," <u>Protein Engineering</u> 7:805-814 (1994)

EXAMINER Philip Gamber 4/15/02	DATE CONSIDERED
---------------------------------------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.